SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw some unusual options trading activity on Thursday. Stock traders acquired 16,073 call options on the company. This is an increase of 70% compared to the typical daily volume of 9,460 call options.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Insiders Place Their Bets

In other news, Director Katherine Bach Kalin acquired 63,400 shares of SELLAS Life Sciences Group stock in a transaction on Wednesday, November 19th. The stock was acquired at an average cost of $1.59 per share, with a total value of $100,806.00. Following the transaction, the director owned 104,400 shares of the company’s stock, valued at approximately $165,996. This trade represents a 154.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.40% of the company’s stock.

Institutional Trading of SELLAS Life Sciences Group

Several hedge funds have recently made changes to their positions in SLS. Virtu Financial LLC lifted its position in shares of SELLAS Life Sciences Group by 30.9% during the 1st quarter. Virtu Financial LLC now owns 53,861 shares of the company’s stock valued at $58,000 after buying an additional 12,706 shares during the last quarter. Anson Funds Management LP boosted its position in shares of SELLAS Life Sciences Group by 535.7% in the first quarter. Anson Funds Management LP now owns 7,579,095 shares of the company’s stock valued at $8,185,000 after acquiring an additional 6,386,829 shares during the period. Blair William & Co. IL purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $35,000. Simon Quick Advisors LLC purchased a new position in SELLAS Life Sciences Group during the second quarter worth about $44,000. Finally, ProShare Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the second quarter worth approximately $43,000. 17.38% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock opened at $1.74 on Friday. The firm has a market cap of $247.85 million, a price-to-earnings ratio of -6.21 and a beta of 2.51. SELLAS Life Sciences Group has a 52 week low of $0.77 and a 52 week high of $2.48. The firm’s 50-day simple moving average is $1.73 and its two-hundred day simple moving average is $1.76.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Analysts forecast that SELLAS Life Sciences Group will post -0.57 earnings per share for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.